RxDoctor Payments Data

Eric Burns

Optometrist · Elizabeth City, NCNPI 1477597029

Payments from drug & device makers

$2,556in general payments, 2019–2025

Across 92 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$619
  • Notal Vision, Inc.$370
  • Mallinckrodt Hospital Products Inc.$319
  • Biotissue Holdings Inc.$175
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$158
  • Bausch & Lomb Americas Inc.$130
  • plus $784 from 14 others

What the payments were for

  • Speaking & faculty fees$37014%
  • Food & beverage$2,08682%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,556 in reported general payments places this provider in the 75th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$412,063
Medicare patients
2,585
Services billed
4,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine106$143,924
LumiganBimatoprost100$47,755
CombiganBrimonidine Tartrate/Timolol72$36,507
XiidraLifitegrast24$34,014
Alphagan PBrimonidine Tartrate59$21,015
Travoprost61$16,196
Cyclosporine25$15,635
TyrvayaVarenicline Tartrate16$14,025
RocklatanNetarsudil Mesylat/Latanoprost16$13,055
VyzultaLatanoprostene Bunod13$12,927
Latanoprost871$12,579
Prednisolone Acetate212$8,081
Brimonidine Tartrate116$5,775
Timolol Maleate306$4,548
Bepotastine Besilate11$4,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$111$249,201337 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$130$46,94137 claims
Oyster Point Pharma, Inc.Tyrvaya$19$14,02516 claims
Aerie Pharmaceuticals, Inc.Rocklatan$13$13,05516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Elizabeth City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →